Is the NIB share price benefitting from Medibank's woes?

Has Medibank's bad week been a good one for rival NIB? Let's investigate.

| More on:
A woman sits on sofa pondering a question.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Medibank has had one of the worst weeks in its history on the ASX
  • The company is in the midst of dealing with a major cybersecurity incident
  • But how is this affecting rival NIB?

Is the NIB Holdings Limited (ASX: NHF) share price benefitting from the woes of its arch-rival Medibank Private Ltd (ASX: MPL) this week?

Medibank has certainly had one of the worst weeks in its eight years or so of its public history. The company suffered a well-publicised cyber attack earlier this month which left potentially millions of customers' healthcare data exposed.

Medibank shares went into a trading halt on this news on 13 October and again last week, only returning back to the markets yesterday.

But investors were brutal in their reception of the ASX health insurance provider. Medibank closed at $2.87 a share yesterday, a good 18.2% or so from its pre-halt levels.

The company initially fell again today, down to a new 52-week low of $2.76. However, it has recovered since then and is presently up by 0.70% at $2.89 a share.

So how is the NIB share price reacting to all of this news in its backyard?

Is the NIB share price benefitting from Medibank's woes?

Well, if you thought NIB shares would be the main beneficiaries of its rivals' woes, you'd be dead wrong. For one, NIB shares are deep in the red today, nursing a loss of 1.6% to $6.65 a share.

But NIB shares have been on the slide for weeks now. In fact, the company began falling dramatically in value from 13 October onwards, around the date the Medibank cyberattack became public knowledge.

However, this could be something of a coincidence. For on that date, NIB shares returned from a trading halt of their own. But this had nothing to do with cybersecurity or Medibank.

As we covered at the time, NIB shares were halted so that the company could conduct a capital raising. NIB ended up raising $135 million to facilitate its expansion plans into the national disability insurance scheme (NDIS). NIB intends to become a Plan Manager with its acquisition of Maple Plan.

So it seems that investors could have been voicing their disapproval of these plans with the share price drops we saw around then. Or else lowering the NIB share price to the $6.90 that the institutional placement took place at.

Either way, it's certainly a raucous period in both Medibank and NIB's histories. But we can conclude that Medibank's share price woes of late don't seem to be benefitting the NIB share price at all.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Healthcare Shares

Guess which ASX small cap stock is jumping on 'significant milestone'

This stock is ending the week in style. Let's see what is giving its shares a boost today.

Read more »

Healthcare Shares

Are CSL and this ASX 200 healthcare stock buys in January?

Is now a good time to pick up these shares? Let's see what analysts are saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Communication Shares

2 ASX shares expected to report strong earnings this quarter

Analysts expect a strong set of upcoming numbers for these ASX heavyweights

Read more »

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »